MX2018004406A - Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae. - Google Patents

Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.

Info

Publication number
MX2018004406A
MX2018004406A MX2018004406A MX2018004406A MX2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A MX 2018004406 A MX2018004406 A MX 2018004406A
Authority
MX
Mexico
Prior art keywords
klebsiella pneumoniae
monoclonal antibody
antibody targeting
bactericidal
bactericidal monoclonal
Prior art date
Application number
MX2018004406A
Other languages
English (en)
Inventor
Mirkina Irina
Nagy Estzer
Nagy Gábor
Szijarto Valeria
Miguel Guachalla Luis
Visram Zehra
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of MX2018004406A publication Critical patent/MX2018004406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/26—Klebsiella (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

Un anticuerpo IgG monoclonal bactericida humano o humanizado que reconoce específicamente el antígeno D-galactán-II de la Klebsiella pneumoniae O1 el cual se caracteriza por una actividad de CDC bactericida, su método de producción, uso médico y diagnóstico.
MX2018004406A 2015-10-16 2016-10-14 Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae. MX2018004406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15190136 2015-10-16
PCT/EP2016/074728 WO2017064258A1 (en) 2015-10-16 2016-10-14 Bactericidal monoclonal antibody targeting klebsiella pneumoniae

Publications (1)

Publication Number Publication Date
MX2018004406A true MX2018004406A (es) 2019-07-01

Family

ID=54359802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004406A MX2018004406A (es) 2015-10-16 2016-10-14 Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.

Country Status (13)

Country Link
US (1) US20180298084A1 (es)
EP (1) EP3362474A1 (es)
JP (1) JP2018533938A (es)
KR (1) KR20180084793A (es)
CN (1) CN108602880A (es)
AU (1) AU2016336901A1 (es)
BR (1) BR112018007483A2 (es)
CA (1) CA3000901A1 (es)
IL (1) IL258475A (es)
MX (1) MX2018004406A (es)
RU (1) RU2018117651A (es)
WO (1) WO2017064258A1 (es)
ZA (1) ZA201802136B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689090B (zh) 2016-08-05 2023-12-26 免疫医疗有限责任公司 抗o2抗体及其用途
KR20190064636A (ko) * 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
KR102581500B1 (ko) * 2021-01-20 2023-09-20 서울대학교산학협력단 폐렴간균 독소-항독소 시스템을 표적으로 하는 항균 펩타이드 및 화합물, 및 이들의 용도
KR102657660B1 (ko) * 2021-06-15 2024-04-15 경상국립대학교산학협력단 폐렴간균 검출용 신규한 펩타이드
WO2023025173A1 (zh) * 2021-08-25 2023-03-02 舒泰神（北京）生物制药股份有限公司 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2007038876A1 (en) * 2005-10-04 2007-04-12 Inimex Pharmaceuticals Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN105734678B (zh) 2010-07-16 2019-11-05 阿迪马布有限责任公司 合成多核苷酸文库
WO2012146630A1 (en) * 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
US20150197558A1 (en) * 2013-09-26 2015-07-16 Trellis Bioscience, Llc Binding moieties for biofilm remediation

Also Published As

Publication number Publication date
RU2018117651A (ru) 2019-11-20
AU2016336901A1 (en) 2018-05-10
BR112018007483A2 (pt) 2018-10-23
ZA201802136B (en) 2019-09-25
KR20180084793A (ko) 2018-07-25
IL258475A (en) 2018-05-31
CA3000901A1 (en) 2017-04-20
JP2018533938A (ja) 2018-11-22
CN108602880A (zh) 2018-09-28
WO2017064258A1 (en) 2017-04-20
US20180298084A1 (en) 2018-10-18
EP3362474A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
MX2018004406A (es) Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
PH12016502518A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
MX2018011633A (es) Diagnostico no invasivo de esteatohepatitis no alcoholica.
IL281272A (en) Humanized antibodies against C5 and their uses
MA39821A (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
IL274951A (en) Human antibodies directed against human tissue factor
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
EP3778636A4 (en) ANTI-CD27 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED MEDICAL USE
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
MX2017011480A (es) Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo.
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
MX2014010987A (es) Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
EP3735423A4 (en) NEO-201 MONOCLONAL ANTIBODY FOR TREATMENT OF HUMAN CARCINOMA
MX2018012061A (es) Inhibidor monovalente de la interaccion hutnfr1.
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
IL269655A (en) ERBB-2 targeting agent and bispecific antibody with antigen binding sites that bind epitopes on the extracellular part of ERB-2 and ERBB-3, for the treatment of ERBB-2, ERBB-2/ERBB-3 positive cancer tumor in particular
EP3524624A4 (en) ANTI-CD27 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF, AND ITS MEDICAL USE
EA201692560A1 (ru) Моноклональные антитела против эпитопа her2 и способы их применения